NBDC Research ID: hum0240.v1
SUMMARY
Aims: To explore molecular targets of primary central nervous system lymphoma (PCNSL)
Methods: Target amplicon sequencing analysis was performed using Target Capture technology (NGS) on Cancer Panel
Participants/Materials: PCNSL patients
| Dataset ID | Type of Data | Criteria | Release Date |
|---|---|---|---|
| JGAS000258 | NGS (Target Capture) | Controlled-access (Type I) | 2020/10/30 |
*Data users need to apply an application for Using NBDC Human Data to reach the Controlled-access Data. Learn more
MOLECULAR DATA
| Participants/Materials | PCNSL (ICD10: C859): 28 cases |
| Targets | Target Capture |
| Target Loci for Capture Methods | 409 genes (Ion Ampliseq Comprehensive Cancer Panel) |
| Platform | Thermo Fisher Scientific [Ion Torrent] |
| Library Source | DNAs extracted from primary tumor tissues and peripheral blood cells |
| Cell Lines | - |
| Library Construction (kit name) | Ion AmpliSeq™ Library Kit 2.0 |
| Fragmentation Methods | FuPa Reagent (Thermo Fisher Scientific) |
| Spot Type | Paired-end |
| Read Length (without Barcodes, Adaptors, Primers, and Linkers) | 100 bp |
| Japanese Genotype-phenotype Archive Dataset ID | JGAD000361 |
| Total Data Volume | 26 GB（fastq） |
| Comments (Policies) | NBDC policy |
DATA PROVIDER
Principal Investigator: Ryuya Yamanaka
Affiliation: Laboratory of Molecular Targeted Therapy for Cancer, Kyoto Prefectural University of Medicine
Project / Group Name: Genome-wide analysis in patients with primary central nervous system lymphomas.
Funds / Grants (Research Project Number):
| Name | Title | Project Number |
|---|---|---|
| KAKENHI Grant-in-Aid for Scientific Research (B) | Exploring molecular targets for primary central nervous system lymphomas based on genome-wide analysis. | 16H05441 |
| KAKENHI Grant-in-Aid for Scientific Research (B) | Development of molecular targeted therapy for primary central nervous system lymphomas. | 24390347 |
PUBLICATIONS
| Title | DOI | Dataset ID | |
|---|---|---|---|
| 1 | Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma | doi: 10.18632/oncotarget.25463 | JGAD000361 |
| 2 |
USRES (Controlled-access Data)
| Principal Investigator | Affiliation | Country/Region | Research Title | Data in Use (Dataset ID) | Period of Data Use |
|---|---|---|---|---|---|
